CyTIX
CyTIX specializes in regenerative medicine and longevity medical products, aiming to expand the implementation of longevity healthcare and support clinics involved in preventive and longevity medicine. The company is dedicated to collecting and providing global information on longevity medicine to healthcare professionals, fostering a society with increasing clinics that focus on extending healthy life expectancy. They are actively involved in developing advanced therapies such as NAD+ therapy, stem cell serum/exosome therapy, NK cell therapy, fusion cell therapy (DCF dendritic cell therapy), and bio-artificial pancreatic islets. CyTIX also engages in clinical research and innovative treatments targeting aging, cancer, and immune system enhancement, including next-generation immunotherapies like DCF dendritic cell therapy.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Characterized conditioned media and extracellular-vesicle preparations
Conditioned media and extracellular-vesicle preparations derived from adipose, dental pulp, umbilical cord, and bone marrow cell cultures intended as biologic adjuncts for translational or clinical regenerative use.
Clinical-grade NMN formulations with protocol package
Vialed NMN preparations intended for clinical administration bundled with protocol documentation, patient materials, dosing guidance (including animal-to-human translation), and cold-storage instructions for clinical adoption.
Macro-encapsulated islet device (research prototype)
Preclinical research prototype of a macro-encapsulated pancreatic islet device using hydrogel/agarose encapsulation, polymer surface modification, and sustained growth-factor release to support subcutaneous implantation without systemic immunosuppression.
Characterized conditioned media and extracellular-vesicle preparations
Conditioned media and extracellular-vesicle preparations derived from adipose, dental pulp, umbilical cord, and bone marrow cell cultures intended as biologic adjuncts for translational or clinical regenerative use.
Clinical-grade NMN formulations with protocol package
Vialed NMN preparations intended for clinical administration bundled with protocol documentation, patient materials, dosing guidance (including animal-to-human translation), and cold-storage instructions for clinical adoption.
Macro-encapsulated islet device (research prototype)
Preclinical research prototype of a macro-encapsulated pancreatic islet device using hydrogel/agarose encapsulation, polymer surface modification, and sustained growth-factor release to support subcutaneous implantation without systemic immunosuppression.
Services
Consulting to design and implement clinic-ready protocols for NAD+ precursor supplementation across multiple administration routes, with dosing guidance, patient materials, administration workflow, and cold-chain handling instructions.
Implementation and monitoring service for IV NMN administration including dosing schedules, baseline and follow-up metabolic biomarkers (insulin, HOMA indices, glucose, HbA1c), and recommendations for sustaining effects with lifestyle interventions.
Research collaboration, quality-control, and supply of characterized conditioned media and extracellular-vesicle preparations derived from multiple tissue sources for use as clinical/regenerative adjuncts.
Outsourced cell-culture services supporting immune-cell therapies and antigen-presenting cell processes, including process development, on-site processing options, and delivery of product for infusion.
Collaborative R&D for macro-encapsulated islet device concepts intended for subcutaneous implantation with immunoisolation, retrievability, and engraftment-support strategies.
Pre- and post-treatment flow-cytometry immunophenotyping to monitor immune cell subsets and support clinical decision-making around immune-cell therapies.
Consulting to design and implement clinic-ready protocols for NAD+ precursor supplementation across multiple administration routes, with dosing guidance, patient materials, administration workflow, and cold-chain handling instructions.
Implementation and monitoring service for IV NMN administration including dosing schedules, baseline and follow-up metabolic biomarkers (insulin, HOMA indices, glucose, HbA1c), and recommendations for sustaining effects with lifestyle interventions.
Research collaboration, quality-control, and supply of characterized conditioned media and extracellular-vesicle preparations derived from multiple tissue sources for use as clinical/regenerative adjuncts.
Outsourced cell-culture services supporting immune-cell therapies and antigen-presenting cell processes, including process development, on-site processing options, and delivery of product for infusion.
Collaborative R&D for macro-encapsulated islet device concepts intended for subcutaneous implantation with immunoisolation, retrievability, and engraftment-support strategies.
Pre- and post-treatment flow-cytometry immunophenotyping to monitor immune cell subsets and support clinical decision-making around immune-cell therapies.
Expertise Areas
- NAD+ metabolism and sirtuin pathway mechanisms
- Clinical program design for NAD+ precursor therapies
- Translational dosing, pharmacokinetics and dose-conversion for NAD+ precursors
- Safety assessment and monitoring for small-molecule biologic supplements
Key Technologies
- NAD+ precursor supplementation (NMN/NR)
- Clinical pharmacokinetics and absorption pathways for small biologic precursors
- Sirtuin pathway modulation
- Allometric dose translation (animal-to-human)
News & Updates
Longevity (Longevity) intensive course at NUS Singapore, focusing on longevity medicine.
Participation in the 2022 private medical practice festival, showcasing private medical treatments.
Publication in the journal 'nature' sister magazine biopharmadealmakers about CyTIX.
Longevity (Longevity) intensive course at NUS Singapore, focusing on longevity medicine.
Participation in the 2022 private medical practice festival, showcasing private medical treatments.
Publication in the journal 'nature' sister magazine biopharmadealmakers about CyTIX.